- Fee assured
- Verified this account
You'll need to contact this healthcare professional to check their availability
General cardiology including investigation of new cardiac symptoms such as chest pain, breathlessness, palpitations, blackouts and fainting.
Treatment of cardiac diseases including hypertension and heart failure.
Specialist interests include Cardio-Oncology which is the cardiovascular health issues in cancer patients including heart failure induced by chemotherapy, radiotherapy and novel cancer treatments such as Herceptin® (trastuzumab). Dr. Lyon is currently president of the British Cardio-Oncology Society, chair of the Cardio-Oncology study group of the Heart Failure Association of the European Society of Cardiology and cardiology advisor to Macmillan Cancer.
Takotsubo cardiomyopathy, also known as acute stress cardiomyopathy or ‘broken heart syndrome’.
Heart problems secondary to systemic diseases such as rheumatological diseases
Areas of interest
General cardiology; Heart Failure; Cardiomyopathy; Hypertension; Arrhythmias; Takotsubo Syndrome; Cardio-Oncology including chemotherapy cardiotoxicity and heart problems in cancer patients; Pericardial diseases; Cardiac complications of systemic inflammatory diseases including rheumatoid arthritis; Gene therapy
Current NHS consultant posts held
Senior Lecturer and Honorary Consultant Cardiologist
Royal Brompton Hospital
Gene therapy and biological therapies for cardiac repair
Cardio-Oncology: Chemotherapy cardiotoxicity and cardiac problems in cancer patients
Stress and the heart
Winner of the Inaugural Bernard and Joan Marshall Young Investigator award: British Society for Cardiovascular Research (BSCR) 2010
Imperial College Research Excellence Award 2010
British Cardiac Society Young Investigator award - Basic Science: Winner 2009
Medical Research Society The Raftery Prize in Cardiovascular Sciences 2008
Royal Society of Medicine 2007 Cardiology Section President’s Medal Winner
Medical Research Council Clinical Research Training Fellowship 2005
Immune checkpoint inhibitors and cardiovascular toxicity. Lyon AR et al.
Lancet Oncology 2018 Sep;19(9):e447-e458.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. Matthews A et al. BMJ. 2018 Oct 8;363:k3845.
Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Pareek N et al. Eur J Heart Fail. 2018 Sep 6. doi: 10.1002/ejhf.1292.
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Chari A et al. Blood Advances 2018 Jul 10;2(13):1633-1644.
Fourth universal definition of myocardial infarction (2018). Thygesen K et al. Eur Heart J. 2018 Aug 25. doi: 10.1093/eurheartj/ehy462.
Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. Lancellotti P et al. Eur Heart J. 2018 Aug 6. doi: 10.1093/eurheartj/ehy453.
International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Ghadri JR et al. Eur Heart J. 2018 Jun 7;39(22):2032-2046.
International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Ghadri JR et al. Eur Heart J. 2018 Jun 7;39(22):2047-2062.
Audit of a tertiary heart failure outpatient service to assess compliance with NICE guidelines Guha K et al. Clin Med (Lond). 2016 Oct;16(5):407-411.
Challenges of Chronic Cardiac Problems in Survivors of Takotsubo Syndrome Morley-Smith AC, Lyon AR. Heart Fail Clin. 2016 Oct;12(4):551-7.
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL et al. Eur Heart J. 2016 37(36):2768-2801.
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Greenberg B et al. Lancet. 2016 387(10024):1178-86.
Current state of knowledge on Takotsubo Syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Lyon AR et al. Eur J Heart Fail. 2016 Jan;18(1):8-27.
Courses offered to GPs
How to manage diastolic dysfunction in primary care
Heart problems in cancer patients
Stress and the heart
Update in hypertension
- Medicine Oxford University 1995
Reference number 4530330
Professional bodies (positions held - last 3 yrs)
- Board member Heart Failure Association of European Society of Cardiology 2016
- Member European Society of Cardiology Cardio-Oncology Council 2018
- President British Cardio-Oncology Society 2016
Details of entry to specialist register
- Cardiology, 2012
Affiliations / memberships
Member of the ESC Heart Failure Association Board (elected April 2016-present)
Member of the ESC Cardio-Oncology Council (elected 2018-present)
Chair of HFA Cardio-Oncology Study Group (2016-present)
Chair of HFA Takotsubo Syndrome Study Group (2016-present)
President of the British Cardio-Oncology Society (2014- present)
Cardiology advisor to Macmillan Cancer (2015-present)